Login to Your Account



Millennium's Velcade Granted Approval For Multiple Myeloma

By Randall Osborne


Thursday, May 15, 2003
Bringing a new treatment option for patients with the fast-killing blood cancer multiple myeloma, Millennium Pharmaceuticals Inc. won FDA approval of the proteasome inhibitor Velcade (bortezomib) and plans to launch it next week. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription